We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to declining drug franchises.

Shares of Sage Therapeutics stock opened at $7.14 on Wednesday. The company has a market cap of $438.97 million, a P/E ratio of -1.28 and a beta of 0.94. The firm’s 50 day moving average price ...

Shares of SAGE stock opened at $7.14 on Wednesday. The company has a market capitalization of $438.97 million, a P/E ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a fifty-two week low ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Biogen Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...